Evidence map›Paper›PMID 30177727›Full record

ArticleScientific reports2018

A new meroterpenoid functions as an anti-tumor agent in hepatoma cells by downregulating mTOR activation and inhibiting EMT.

Haoqiang Wan, Jiemei Li, Keda Zhang, Xiaoting Zou, Lanlan Ge, Fuqiang Zhu, Huirong Zhou, Minna Gong, Tianwa Wang, Dongling Chen and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Marine-DerivedMarine drugs · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Haoqiang WanCenter Lab of Longhua Branch, Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, Shenzhen, 518120, Guangdong Province, China.
Jiemei LiCenter Lab of Longhua Branch, Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, Shenzhen, 518120, Guangdong Province, China.
Keda ZhangCenter Lab of Longhua Branch, Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, Shenzhen, 518120, Guangdong Province, China.
Xiaoting ZouCenter Lab of Longhua Branch, Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, Shenzhen, 518120, Guangdong Province, China.
Lanlan GeCenter Lab of Longhua Branch, Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, Shenzhen, 518120, Guangdong Province, China.
Fuqiang ZhuDepartment of pathology (Longhua Branch), Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, Shenzhen, 518120, Guangdong Province, China.
Huirong ZhouDepartment of pathology (Longhua Branch), Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, Shenzhen, 518120, Guangdong Province, China.
Minna GongDepartment of pathology (Longhua Branch), Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, Shenzhen, 518120, Guangdong Province, China.
Tianwa WangDepartment of pathology (Longhua Branch), Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, Shenzhen, 518120, Guangdong Province, China.
Dongling ChenDepartment of pathology (Longhua Branch), Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, Shenzhen, 518120, Guangdong Province, China.
Shusong PengDepartment of pathology (Longhua Branch), Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, Shenzhen, 518120, Guangdong Province, China. shusongpeng@163.com.
Boping ZhouCenter Lab of Longhua Branch, Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, Shenzhen, 518120, Guangdong Province, China. zhoubp@hotmail.com.
Xiaobin ZengCenter Lab of Longhua Branch, Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, Shenzhen, 518120, Guangdong Province, China. zengxiaobin1983@163.com.
ShenZhen People’s Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver cancer, also known as primary liver cancer, is cancer that starts in the liver. JNU-144, a new meroterpenoid purified from Lithospermum erythrorhizon, has exhibited promising anticancer activity; however, the molecular mechanisms of action of JNU-144 on malignant cells remain unclear. Our studies revealed that JNU-144 suppressed cell viability and proliferation in hepatoma cells by downregulating mTOR activation. Meanwhile, JNU-144 activated the intrinsic apoptosis pathway and subsequently triggered apoptotic cell death in SMMC-7721 cells. We also found that JNU-144 inhibited the epithelial-mesenchymal transition in both SMMC-7721 and HepG2 cells through reprogramming of epithelial-mesenchymal transition (EMT)-related gene expression or regulating protein instability. These findings indicate that JNU-144 exerts potent anticancer activity in hepatoma cells and may be developed as a potential therapeutic drug.

Indexed as

Gene Expression Regulation, NeoplasticAntigens, CDAntineoplastic Agents, Phytogenicbeta CateninCadherinsCarcinoma, HepatocellularCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionHumansLithospermumLiver NeoplasmsPlant ExtractsSignal TransductionTerpenesAntigens, CDAntineoplastic Agents, Phytogenicbeta CateninCadherinsCDH2 protein, humanCTNNB1 protein, humanMTOR protein, humanPlant ExtractsTerpenesTOR Serine-Threonine KinasesVimentinVIM protein, humanZEB1 protein, humanZinc Finger E-box-Binding Homeobox 1

Identifiers

PMID30177727
PMCPMC6120861
OpenAlexW2889300460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.